Bio-Techne's stock plummeted 5.15% during intraday trading on Friday.
The decline follows price target reductions from at least two analysts. Deutsche Bank cut its target on Bio-Techne to $66 from $75, while maintaining a buy rating. Separately, Stephens adjusted its price target to $68 from $80.
According to FactSet data, Bio-Techne has an average rating of overweight. The analyst actions likely contributed to the negative investor sentiment and selling pressure during the session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments